Pharma Industrial India Newsletter [ 2024-07-25]

Open in new window

Pharmaindustrial Mediakit Articles Interviews Appointments Events Magazines

Featured News

Union Budget 2024-25: Government Exempts Duties on Essential Medical Materials

Nirmala Sitharaman has presented the Union Budget 2024-25 in the Parliament today with a special focus on medical equipment.

Gericke Unveils GSF Lab System for Drug Development

Gericke has rolled out GFS LAB for continuous manufacturing of formulation development for drug development.

Alembic Pharma Received FDA Approval for Fluphenazine Hydrochloride Tablets

Alembic Pharmaceuticals Ltd. has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fluphenazine Hydrochloride Tablets USP,...

Gland Pharma Gets Tentative Approval from USFDA for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma Ltd. has secured tentative approval from the United States Food and Drug Administration (USFDA) for Latanoprostene Bunod Ophthalmic Solution, 0.024 percent.

Lupin and Huons to Commercialize Cyclosporine Ophthalmic Nanoemulsion in Mexico

Lupin has signed a license and supply deal with Huons Co. Ltd. for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion, a 0.4mL Single-use Vial, in Mexico.

BHS-Sonthofen Launches New Test Center for Process Technology

BHS-Sonthofen has inagurated a new test center in Sonthofen.

Rusan Pharma API Plant in Ankleshwar Gets USFDA GMP Approval

Rusan Pharma has announced that the United States Food and Drug Administration (USFDA) has granted Good Manufacturing Practice (GMP) approval for its Active Pharmaceutical Ingredient (API) facility...

Biolyst Scientific Announced as New Brand Name to Encompass EMS and Azer

Biolyst Scientific has announced its new brand name, reflecting the integration of Electron Microscopy Sciences (EMS) and Azer Scientific.

Glenmark Gets ANDA Approval for Topiramate Capsules

Glenmark Pharmaceuticals Ltd. has been granted final approval by the United States Food and Drug Administration (US FDA) for Topiramate Capsules USP, 15 mg and 25 mg.

Avallano Unveils AI-Based Clinical Research Protocol Assistant ProtocolCopilot

Avallano has introduced ProtocolCopilot, an innovative AI-driven clinical research protocol assistant designed to transform the way biopharmaceutical companies and clinical research sites manage and...

Lupin Gets Tentative Approval from US FDA for RLD Sutab

Lupin has secured tentative approval from US FDA for its Abbreviated New Drug Application for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g, to market...

Merck Begins Commercial Production of GMP-Compliant Manufacturing Line for CCM in China

Merck has started the commercial production of its first GMP (Good Manufacturing Practices) compliant manufacturing line for cell culture media (CCM) in China.

Alembic Pharma Gets USFDA Tentative Approval for Selexipag for Injection

Alembic Pharmaceuticals has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Selexipag for Injection, 1,800 mcg/vial.

Nona Biosciences Signs Partnership Deal with Alaya.bio to Advance CAR-T Cell Therapy

Nona Biosciences has entered into a collaboration agreement with Alaya. bio to precisely target and reprogram cells in situ and thus to significantly simplify the way CAR-T cell therapies in particular...

Dr. Reddy's Laboratories Launches Muslaxin in Russia

Dr. Reddy's Russia arm, part of the global pharmaceutical company Dr. Reddy’s Laboratories, has introduced Muslaxin (INN Ibuprofen 400 mg + Chlorzoxazone 500 mg), the first combination drug...

ProofPilot Announces Closing of its Series C Funding

ProofPilot has announced the closing of its Series C financing, led by Sopris Capital with Mitsui & Co. (USA), Inc. participating.

The Double-Edged Sword of Online Pharmacies: Balancing Access and Security in the Digital Age

In an era where digital convenience reigns supreme, online pharmacies have revolutionized healthcare delivery. These platforms offer unprecedented access to...

Syntegon Elevating Pharma Standards with New Technologies

Q: Tell us about Syntegon key offerings related to pharma industry and how does its products distinguish itself from its global competitors? Dr. Andreas...

This message and any attachments are confidential and privileged and intented for the use of the addressee only. If you have received this communication in error, please notify the sender by replay e-mail and delete this message from your system. Please note that Internet e-mail guarantees neither the confidentiality nor the proper receipt of the message sent. The data deriving from our correspondence with you are included in a file of OMNIMEDIA, S.L. which exclusive purpose is to manage the communications of the company; under the understanding that, in maintaining said correspondence, you authorize the treatment of such data for the mentioned purpose. You are entitled to exercise your rights of access, rectification, cancellation and opposition by addressing such written application to address C/ Pollensa, 2, Edif. Artemisa of. 12 de LA ROZAS (28290 - MADRID) enclosing your NIF or identifying document photocopies of.

Unsubscribe